Compare LBRX & TRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | TRNS |
|---|---|---|
| Founded | 2015 | 1964 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 958.7M | 861.5M |
| IPO Year | N/A | 1995 |
| Metric | LBRX | TRNS |
|---|---|---|
| Price | $31.14 | $86.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $46.60 | ★ $116.00 |
| AVG Volume (30 Days) | ★ 351.9K | 152.8K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | N/A | ★ $331,877,000.00 |
| Revenue This Year | N/A | $21.75 |
| Revenue Next Year | N/A | $7.55 |
| P/E Ratio | ★ N/A | $154.19 |
| Revenue Growth | N/A | ★ 19.20 |
| 52 Week Low | $13.40 | $50.23 |
| 52 Week High | $35.35 | $95.22 |
| Indicator | LBRX | TRNS |
|---|---|---|
| Relative Strength Index (RSI) | 48.93 | 45.88 |
| Support Level | $26.75 | $85.90 |
| Resistance Level | $34.10 | $94.36 |
| Average True Range (ATR) | 1.98 | 3.89 |
| MACD | -0.32 | -0.71 |
| Stochastic Oscillator | 31.75 | 19.06 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.